Skip to main content

News & Events


Studies Presented at ESCMID Global Demonstrate the Clinical Utility of SeptiCyte® RAPID in Patients Suspected of Sepsis

Immunexpress, Pty Ltd., a molecular diagnostic company focused on improving outcomes for suspected sepsis patients, today announced the presentation of two posters evaluating SeptiCyte® RAPID at the European Society of Clinical Microbiology and Infectious Diseases (ESCMID Global) 2024, to take place from April 27 – 30 in Barcelona, Spain.
April 19, 2024

Trio of Diagnostics CEOs Weigh In On Upcoming Challenges

During this podcast, Barnaby Pickering speaks to Rollie Carlson, CEO of Immunexpress, developer of Septicyte, a test for sepsis, and two other CEOs, about why their products are transformative.
February 9, 2024

With Expanded FDA Clearance for Sepsis Test, Immunexpress Furthers Commercialization Strategy

After getting expanded clearance from the US Food and Drug Administration for its sepsis test, Immunexpress is continuing its commercialization path and working on further expansions for its assay.
January 22, 2024

Accurate Identification of Sepsis using SeptiCyte® RAPID and Comparison with other Biomarkers Presented at Society of Critical Care Medicine (SCCM) Critical Care Congress 2024

Immunexpress, Pty Ltd., a molecular diagnostic company focused on improving outcomes for suspected sepsis patients, today announced  that data validating the use of SeptiCyte® RAPID in differentiating sepsis from systemic inflammatory response syndrome (SIRS) was selected for presentation on Sunday, January 21, during the Society of Critical Care Medicine (SCCM) 2024 Critical Care Congress in Phoenix, Arizona, January 21 to 23, 2024.
January 22, 2024

SeptiCyte RAPID® By Immunexpress Receives Regulatory Clearance from Australian Therapeutic Goods Administration (TGA)

SeptiCyte® RAPID has received regulatory clearance by the Australian Therapeutic Goods Administration (TGA). The clearance of the company's flagship medical device by the regulatory body allows for the sale, use and further commercial testing of SeptiCyte RAPID throughout Australia to differentiate infection-positive (sepsis) from infection-negative systemic inflammation response syndrome.
January 17, 2024

Immunexpress Announces U.S. FDA Clearance of EDTA Blood Compatible Cartridges for SeptiCyte RAPID®

The U.S. Food and Drug Administration has cleared EDTA blood compatible cartridges for use with SeptiCyte RAPID®. The updated SeptiCyte® RAPID cartridges add undiluted EDTA blood as a validated sample type within the U.S. healthcare market and have been available on the European market since August 2022.
January 4, 2024

How Cross-Training and Extreme Ownership Help You Advance Your Career

In this podcast episode Rollie Carlson discusses how he prepared for new opportunities, the benefits of extreme ownership, balancing company vision and mission, alignment of everyone in a company, why sepsis is such a big problem, and what Immunexpress is doing to help clinicians better manage sepsis patients.
December 6, 2023

Data Presentation at Association for Molecular Pathology 2023 Validates Performance of SeptiCyte® RAPID in Immunocompromised Patients and Patients on Immunosuppressive Therapy

Immunexpress, Pty Ltd., a molecular diagnostics company focused on rapid diagnosis and improved outcomes for suspected sepsis patients, today announced a poster presentation validating the utility of SeptiCyte® RAPID in patients who are immunocompromised or are receiving immunosuppressive therapy at the Association for Molecular Pathology (AMP) 2023 Annual Meeting. The poster, entitled "Performance of SeptiCyte® RAPID for Determining Probability of Sepsis in Immunocompromised Patients or Those on Immunosuppressant Therapy," is designated as Poster # ID042 and will be presented on November 17, from 9:15- 10:15 a.m. MT, in Salt Lake City, Utah.
November 17, 2023

Improving Outcomes For Patients With Sepsis

Dr. Rolland Carlson, PhD, Chief Executive Officer of Immunexpress, Inc., was a guest on Progress, Potential and Possibilities. He discussed how SeptiCyte™  has the potential to differentiate infection earlier, faster and more accurately than finding the invading pathogen because it is independent of whether or not the pathogen is present in the sample.
November 2, 2023

Developing technology for faster sepsis diagnosis

Ian Bolland is joined by Rollie Carlson, CEO of Immunexpress, as he provides some insight into the challenges of diagnosing sepsis and the technology that is being developed to tackle it.
October 5, 2023

CHEST 2023 Poster Demonstrates the Utility of SeptiCyte® RAPID in Antibiotic Administration and Sepsis Bundle Compliance

Immunexpress a molecular diagnostics company focused on rapid diagnosis and improved outcomes for suspected sepsis patients, today announced a poster presentation demonstrating the usefulness of SeptiCyte® RAPID in conjunction with clinical assessment of sepsis for informing on antibiotic administration and bundle compliance at the annual meeting of the American College of Chest Physicians (CHEST 2023).
October 2, 2023

SeptiCyte® RAPID Receives ICD-10-PCS Code from the U.S. Centers for Medicare & Medicaid Services (CMS)

U.S. Centers for Medicare & Medicaid Services (CMS) has granted an International Classification of diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS) code for Immunexpress' host response molecular test for sepsis, SeptiCyte® RAPID.
September 6, 2023

Nonprofit health system adopts Immunexpress test for detecting sepsis

FirstHealth of the Carolinas, a nonprofit health system licensed for four hospitals in North Carolina, will use Immunexpress’ SeptiCyte Rapid test to help differentiate sepsis-positive cases from patients with infection-negative systemic inflammation.
August 29, 2023

PodcastDX features Septicyte Rapid

Richard Brandon, one of Septicyte's developers, discusses the test and the impact of sepsis with the host of PodcastDX.
August 7, 2023

Immunexpress and University Hospitals Cleveland Medical Center Present Quality Improvement Feasibility with SeptiCyte® RAPID at the 2023 American Association for Clinical Chemistry Annual Scientific Meeting and Clinical Lab Expo

“The early accurate diagnosis of sepsis can be challenging, but recent advancements in FDA-cleared lab tests have introduced new tools that may enhance earlier diagnosis," said Kenneth E. Remy, MD, MHSc, MSCI, FCCM, Center Director, the Blood, Heart, Lung, and Immunology Research Center and the Ellery Sedgwick, Jr. Chair and Distinguished Scientist in Cardiovascular Research at University Hospitals in Cleveland/Case Western Reserve University. AACC-2023-Sepsis 072023
July 25, 2023

Immunexpress Announces Adoption of SeptiCyte® RAPID by FirstHealth of the Carolinas

FirstHealth is among other early adopters integrating the recently FDA cleared SeptiCyte RAPID® test into their hospital sepsis clinical workflow to address diagnostic uncertainty and improve sepsis awareness and bundle compliance.
July 21, 2023

An Interview With Richard Brandon, Chief Scientific Officer at Immunexpress

Despite its prevalence and severe consequences, diagnosing sepsis remains a significant challenge in the healthcare industry. Delve into an enlightening interview with Richard Brandon, the Chief Scientific Officer at Immunexpress, a company at the forefront of revolutionizing sepsis diagnostics.
July 6, 2023

A Diagnostic Dilemma

Sepsis places a significant burden on healthcare and can be challenging to identify early – is there a way to ease the pressure?
June 15, 2023

Better Health Care Tests, Faster

Immunexpress offers a test called SeptiCyte that quickly and accurately indicates the risk of sepsis by measuring RNA from white blood cells. The device can turn around a test within one hour.
June 14, 2023

Why Better Sepsis Diagnosis Results in Better Outcomes

The adoption of innovative approaches, such as SeptiCyte RAPID, to aid in sepsis diagnosis is expected to provide benefits to patients, clinical utility to physicians and financial benefits to hospital and health systems.
June 7, 2023

ICT’s Product Locator: April 2023

SeptiCyte Rapid was included in Infection Control Today’s April product locator. “With SeptiCyte RAPID, we are testing for the first clinical signs of sepsis and generating actionable results quickly. This is critically important because mortality risk increases by 8% as each hour goes by,” said Rollie Carlson, PhD, CEO of Immunexpress.
May 13, 2023

Immunexpress to Present Data at ECCMID 2023 Indicating that SeptiCyte® RAPID Differentiates Sepsis from Non-Sepsis in Patients with Uncertain Initial Diagnosis

For patients initially classified as indeterminate and then reassessed by a forced diagnosis, SeptiCyte RAPID significantly differentiated between SIRS (mean result or SeptiScore® 5.6) and sepsis (mean SeptiScore 7.3) (p=1.31e-07).
April 12, 2023

How Does Your Product Fit And Improve?

In this podcast, Rollie Carlson, Ph.D., discusses developing the right strategic partners and how they can enhance your efforts for product acceptance.
April 5, 2023

Immunexpress to Present Data at ISICEM 2023 Indicating that SeptiCyte® RAPID Outperforms Other Rapid Measures for Sepsis Diagnosis

This study demonstrates that SeptiCyte RAPID is not only a more accurate sepsis diagnostic tool compared to other conventional rapid diagnosis methods but can serve as a crucial first step in the diagnostic and treatment paradigm for patients suspected of sepsis using the Sepsis-3 framework.
April 5, 2023

New Publication Further Validates SeptiCyte® RAPID for Disease Severity Assessment and Triaging in COVID-19 Patients with Extensive Lung Injury

A study in the journal Viruses validates the use of SeptiCyte® RAPID as a tool to measure disease severity in COVID-19 patients, in comparison to a reference method based on chest computed tomography (CT) imaging.
March 21, 2023

New Publication Validates SeptiCyte® RAPID as a Triaging Tool for COVID-19 Patients

A new study in Scientific Reports, a journal in the Nature portfolio, validates the use of SeptiCyte® RAPID as a triaging tool for COVID-19 patients requiring hospitalization and potentially ICU care.
February 3, 2023

Immunexpress Begins US Commercialization of Near-Patient Sepsis Diagnostic Test

This article about Immunexpress and its sepsis diagnostic test was published in GenomeWeb.
February 3, 2023

At AMP 2022, Immunexpress launches rapid test for sepsis requiring two minutes hands-on time

At the Association for Molecular Pathology annual meeting and exposition this week, Immunexpress launched a rapid molecular diagnostic test that could enable ruling in or ruling out sepsis in one hour.
November 10, 2022

Multi-site study confirms the use of undiluted EDTA blood for the SeptiCyte RAPID sepsis assay

Data Validating EDTA Blood as Sample Type for SeptiCyte® RAPID Presented at the Association for Molecular Pathology 2022 Annual Meeting
November 10, 2022

Dr. Rollie Carlson, CEO, Immunexpress: Providing RAPID Detection for Sepsis

DocWire News spoke with Dr. Rollie Carlson, CEO of Immunexpress, to learn more about this cutting-edge technology, and how it can quickly and accurately detect sepsis, and lead to faster treatment.
October 24, 2022

Building a powerful portfolio of sepsis biomarker signatures for therapeutic clinical trials

In this Q&A, Immunexpress Chief Executive Officer Dr Rolland Carlson and Chief Scientific Officer Dr Richard Brandon discuss key aspects for molecular diagnostic discovery and development platforms, including how to best leverage microarray and next-generation sequencing (NGS) tools.
October 21, 2022

Immunexpress Announces the Launch of New SeptiCyte RAPID® CE-IVD EDTA Blood Compatible Cartridges

SeptiCyte® RAPID EDTA blood compatible cartridges were recently launched in the European market, representing a significant development milestone for the identification of pathogens associated with sepsis. This press release and the associated blog posts explore the significance of this development.
October 1, 2022
sepsis diagnosis

A Paradigm Shift In Diagnosing Sepsis

This article from Technology Networks includes an interview with Rolland Carlson, PhD, the CEO of Immunexpress. Rolland describes the paradigm shift in sepsis diagnosis as well as the specifics of how SeptiCyte® RAPID provides a faster and accurate diagnosis, allowing physicians to quickly rule-in or rule-out sepsis.
September 30, 2022

Tips For Obtaining Your 510(k) FDA Clearance

Learn more about the process of getting the lab test for sepsis, SeptiCyte® RAPID, cleared by the FDA. This article from Med Device Online also includes tips for obtaining a 510(k) FDA Clearance for other medical use products.
July 8, 2022

Data presented by Immunexpress collaborator from a study supporting SeptiCyte® RAPID performance for COVID-19 patient triage

At the 32nd ECCMID, Immunexpress and collaborators at Hospital Foch, France, shared research demonstrating that SeptiCyte® RAPID sepsis test can distinguish between COVID-19 patients showing higher extents of lung damage as defined by lung CT scans from those with a milder presentation.
April 19, 2022

Discussing Sepsis Diagnosis with Immunexpress

In this DNA Weekly interview, Immunexpress CEO Dr. Rollie Carlson, discusses why the company is tackling sepsis, explains the challenge of diagnosing sepsis, and details how SeptiCyte® RAPID helps. He also discusses how SeptiCyte® RAPID allows hospital systems to improve their sepsis management quality scores.
December 22, 2021

Immunexpress’ rapid sepsis test receives FDA clearance

Often difficult to diagnosis, sepsis remains a leading cause of morbidity and mortality among intensive care unit (ICU) patients. SeptiCyte® RAPID is the first FDA-cleared sepsis diagnostic to differentiate sepsis from non-infectious systemic inflammation to aid in rapid sepsis diagnosis within approximately one hour.
December 9, 2021

FDA grants 510(k) clearance for Immunexpress’ SeptiCyte RAPID test

This Medical Device Network article highlights our FDA-cleared sepsis diagnostic SeptiCyte® RAPID. The fast sepsis test addresses “a critically unmet need in the ICU,” said Immunexpress Chief Medical Officer, Dr. Roy Davis. SeptiCyte® technology aids physicians in distinguishing sepsis from -infection-negative (SIRS) systemic inflammation in critically ill patients.
December 1, 2021

10 News Brisbane – Device That Can Save Lives from Sepsis Awaiting Australian Regulatory Approval

In this interview with 10 News Brisbane, Dr. Adam Irwin, physician, and senior lecturer of pediatric infectious disease at the University of Queensland, details how deadly a sepsis diagnosis can be for children. Richard Brandon, Chief Scientific Officer of Immunexpress, shares the development of a one-hour sepsis test, SeptiCyte® RAPID, that is awaiting Australian regulatory approval.
September 15, 2021

SeptiCyte® RAPID proved superior sepsis diagnostic compared to lactate and procalcitonin

SeptiCyte® RAPID is a sepsis test that uses peripheral blood gene expression biomarkers to provide accurate sepsis diagnosis in patients presenting with clinical signs of systemic inflammation. Data was presented detailing the superior performance of SeptiCyte® RAPID in differentiating sepsis from non-infectious inflammatory responses at the 2021 IDWeek Conference.
September 14, 2021